ASPIRE-FTD Trial Expands to Fourth Cohort

AviadoBio has announced the expansion of its ASPIRE-FTD clinical trial, a Phase 1/2 study evaluating an investigational gene therapy (AVB-101) for people living with FTD caused by GRN mutations (FTD-GRN). The study is now expanding to a fourth cohort, creating additional opportunities for eligible participants to enroll across sites in the U.S., Canada, and Europe.

This gene therapy approach is designed to deliver a working copy of the GRN gene directly to the brain through a one-time surgical procedure, with the goal of restoring levels of progranulin, a protein that plays a key role in protecting brain cells. Early findings suggest the therapy has been generally well tolerated, though research is still ongoing and no definitive conclusions can yet be drawn.

Clinical trials like ASPIRE-FTD depend on participation from individuals and families impacted by FTD. Representation in research is critical to advancing potential therapies and deepening scientific understanding.

To learn more about this study, including eligibility criteria and how to participate, read the full update from the Association for Frontotemporal Degeneration (AFTD):
https://www.theaftd.org/1ftd-in-the-news/aviadobio-aspire-ftd-cohort4/

Joining the FTD Disorders Registry is one of the easiest ways to stay informed about opportunities like this and to help researchers connect with individuals who may be eligible for current or future studies.